From Bench to Bill: How a Lab Discovery Becomes (or Doesn't Become) an Affordable Treatment
A cancer drug doesn't start as a price tag. It starts on a bench — a researcher noticing that a particular molecule interrupts a particular signal, or that a particular immune cell behaves differently in the presence of a tumor. That's the part of the pipeline I see most directly in my own research on the breast cancer microbiome: it's slow, computational, and has nothing to do with a sticker price. The price only enters the picture much later, and it enters through a set of decisions that have very little to do with biology.
Here's roughly how the pipeline works. A discovery in a lab gets validated, then tested in animal models, then — if it survives that — moves into human clinical trials across three phases, each one larger, slower, and more expensive than the last. Only a small fraction of drugs that enter trials make it to FDA approval. Once a drug is approved, the company that developed it sets a launch price, largely without external constraint — the U.S. is one of the only wealthy countries that doesn't negotiate or cap drug prices at launch. That price then gets negotiated (opaquely) between manufacturers, insurers, and pharmacy benefit managers, and what a patient actually pays depends on their specific insurance, deductible, and whether the drug is on their plan's formulary.
Notice how many of those steps are business and regulatory decisions, not scientific ones. The biology is finished long before the price is set. And the "it costs so much because it's so hard to develop" justification is shakier than it sounds — estimates of what it actually costs to bring a cancer drug to market vary wildly, from a widely-cited $2.7 billion figure down to a median of $648 million found in a more recent study of 10 real cancer drugs. When the number that's supposed to justify the price can differ by billions depending on the study, it's a sign that "cost of discovery" is doing less work in the final price than it seems.
This is why BioPolicy treats "bench" and "bill" as two separate systems that only look connected. Understanding the biology — which is where research like mine lives — tells you almost nothing about what a treatment will cost or who will be able to afford it. That's decided afterward, by policy choices about pricing, insurance, and coverage. If we want cheaper, more accessible cancer treatment, the lever isn't necessarily better science. It's better rules for what happens after the science is done.